tradingkey.logo

Aptorum Group Ltd

APM
1.170USD
+0.050+4.46%
Close 12/24, 13:00ETQuotes delayed by 15 min
8.36MMarket Cap
LossP/E TTM

Aptorum Group Ltd

1.170
+0.050+4.46%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Aptorum Group Ltd

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued, Institutional ownership is very high.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aptorum Group Ltd's Score

Industry at a Glance

Industry Ranking
301 / 501
Overall Ranking
570 / 4682
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Aptorum Group Ltd Highlights

StrengthsRisks
Aptorum Group Limited is a United Kingdom-based clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Its lead projects are ALS-4, SACT-1 and PathsDx Test. ALS-4 is a small drug molecule which appears to target the products produced by bacterial genes that facilitate the successful colonization and survival of the bacterium in the body or that cause damage to the body's systems. SACT-1 is the first repurposed drug candidate to be developed under the Smart-ACT drug discovery platform. The Company's pipeline is also enriched through the co-development of PathsDx Test, a molecular-based rapid pathogen identification and detection diagnostics technology, with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research.
Overvalued
The company’s latest PE is -1.93, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 43.95K shares, decreasing 65.40% quarter-over-quarter.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 6.16.

Financial Health

Currency: USD Updated: 2025-10-27

No financial score is currently available for Aptorum Group Ltd. The Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score
0.00
Change
0

Financials

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

Operational Efficiency

Growth Potential

Shareholder Returns

Aptorum Group Ltd's Company Valuation

Currency: USD Updated: 2025-10-27

The current valuation score of Aptorum Group Ltd is 7.38, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.93, which is -63.84% below the recent high of -0.70 and -1734.40% above the recent low of -35.39.

Score

Industry at a Glance

Previous score
7.38
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 301/501
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-10-27

No earnings forecast score is currently available for Aptorum Group Ltd. The Biotechnology & Medical Research industry's average is 8.04.

Score

Industry at a Glance

Previous score
0.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.
No Data

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The current price momentum score of Aptorum Group Ltd is 6.42, ranking industry_rank/industry_total in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 2.27 and the support level at 1.08, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.49
Change
-0.07

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(3)
Neutral(3)
Buy(0)
Indicators
Value
Direction
MACD(12,26,9)
-0.014
Sell
RSI(14)
40.369
Neutral
STOCH(KDJ)(9,3,3)
26.404
Neutral
ATR(14)
0.096
Low Volatility
CCI(14)
-74.258
Neutral
Williams %R
73.072
Sell
TRIX(12,20)
-0.786
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(5)
Neutral(0)
Buy(1)
Indicators
Value
Direction
MA5
1.146
Buy
MA10
1.197
Sell
MA20
1.268
Sell
MA50
1.378
Sell
MA100
1.624
Sell
MA200
1.332
Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
CGY Investments Ltd
533.58K
--
Jurchen Investment Corp
370.31K
--
Huen (Ian)
137.66K
--
Osaic Holdings, Inc.
5.50K
--
Citi Investment Research (US)
995.00
+5136.84%
SBI Securities Co., Ltd.
7.00
-89.55%
Geode Capital Management, L.L.C.
37.45K
+1.36%
XTX Markets LLC
--
-100.00%
Morgan Stanley & Co. LLC
--
-100.00%
UBS Financial Services, Inc.
--
-100.00%
1
2

Risk Assessment

Currency: USD Updated: 2025-10-27

No risk assessment score is currently available for Aptorum Group Ltd. The Biotechnology & Medical Research industry's average is 3.49. The company's beta value is -0.01. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
0.00
Change
0
Beta vs S&P 500 index
-0.16
VaR
+10.26%
240-Day Maximum Drawdown
+74.12%
240-Day Volatility
+187.83%

Return

Best Daily Return
60 days
+15.56%
120 days
+234.65%
5 years
+554.44%
Worst Daily Return
60 days
-29.96%
120 days
-37.88%
5 years
-38.00%
Sharpe Ratio
60 days
-1.28
120 days
+1.08
5 years
+0.37

Risk Assessment

Maximum Drawdown
240 days
+74.12%
3 years
+94.82%
5 years
+98.41%
Return-to-Drawdown Ratio
240 days
-0.21
3 years
-0.24
5 years
-0.20
Skewness
240 days
+9.95
3 years
+17.40
5 years
+21.26

Volatility

Realised Volatility
240 days
+187.83%
5 years
+178.74%
Standardised True Range
240 days
+14.15%
5 years
+67.47%
Downside Risk-Adjusted Return
120 days
+400.90%
240 days
+400.90%
Maximum Daily Upside Volatility
60 days
+86.97%
Maximum Daily Downside Volatility
60 days
+92.25%

Liquidity

Average Turnover Rate
60 days
+377.01%
120 days
+191.49%
5 years
--
Turnover Deviation
20 days
+615.80%
60 days
+379.64%
120 days
+143.62%

Peer Comparison

Biotechnology & Medical Research
Aptorum Group Ltd
Aptorum Group Ltd
APM
2.69 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
Amicus Therapeutics Inc
FOLD
8.82 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQVIA Holdings Inc
IQV
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Dynavax Technologies Corp
Dynavax Technologies Corp
DVAX
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals Inc
BCRX
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
Krystal Biotech Inc
KRYS
8.46 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Aptorum Group Ltd?

The TradingKey Stock Score provides a comprehensive assessment of Aptorum Group Ltd based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Aptorum Group Ltd’s performance and outlook.

How do we generate the financial health score of Aptorum Group Ltd?

To generate the financial health score of Aptorum Group Ltd, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Aptorum Group Ltd's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Aptorum Group Ltd.

How do we generate the company valuation score of Aptorum Group Ltd?

To generate the company valuation score of Aptorum Group Ltd, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Aptorum Group Ltd’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Aptorum Group Ltd’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Aptorum Group Ltd.

How do we generate the earnings forecast score of Aptorum Group Ltd?

To calculate the earnings forecast score of Aptorum Group Ltd, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Aptorum Group Ltd’s future.

How do we generate the price momentum score of Aptorum Group Ltd?

When generating the price momentum score for Aptorum Group Ltd, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Aptorum Group Ltd’s prices. A higher score indicates a more stable short-term price trend for Aptorum Group Ltd.

How do we generate the institutional confidence score of Aptorum Group Ltd?

To generate the institutional confidence score of Aptorum Group Ltd, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Aptorum Group Ltd’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Aptorum Group Ltd.

How do we generate the risk management score of Aptorum Group Ltd?

To assess the risk management score of Aptorum Group Ltd, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Aptorum Group Ltd’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Aptorum Group Ltd.
KeyAI